Literature DB >> 24582783

Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO).

Corrado Girmenia1, Giovanni Barosi2, Alfonso Piciocchi3, William Arcese4, Franco Aversa5, Andrea Bacigalupo6, Giuseppe Bandini7, Alberto Bosi8, Alessandro Busca9, Elio Castagnola10, Desiree Caselli11, Simone Cesaro12, Fabio Ciceri13, Anna Locasciulli14, Franco Locatelli15, Malgorzata Mikulska16, Livio Pagano17, Arcangelo Prete18, Anna Maria Raiola6, Alessandro Rambaldi19.   

Abstract

This document updates and expands the recommendations on primary prophylaxis of invasive fungal diseases (IFD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients, published in 2009 by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). A consensus process was undertaken to describe and evaluate current information and practice regarding risk stratification and primary antifungal prophylaxis during the pre-engraftment and postengraftment phases after allo-HSCT. The revised recommendations were based on the evaluation of recent literature including a large, prospective, multicenter epidemiological study of allo-HSCT recipients conducted among the GITMO transplantation centers during the period of 2008 to 2010. It is intended as a guide for the identification of types and phases of transplantation at low, standard, and high risk for IFD, according to the underlying disease, transplantation, and post-transplantation factors. The risk stratification was the critical determinant of the primary antifungal approach for allo-HSCT recipients.
Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allogeneic hematopoietic stem cell transplantation (HSCT); Antifungal prophylaxis; Consensus; Fungal infections

Mesh:

Substances:

Year:  2014        PMID: 24582783     DOI: 10.1016/j.bbmt.2014.02.018

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  14 in total

Review 1.  Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia.

Authors:  Anna B Halpern; Gary H Lyman; Thomas J Walsh; Dimitrios P Kontoyiannis; Roland B Walter
Journal:  Blood       Date:  2015-10-26       Impact factor: 22.113

Review 2.  Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies.

Authors:  David J Epstein; Susan K Seo; Janice M Brown; Genovefa A Papanicolaou
Journal:  J Antimicrob Chemother       Date:  2018-01-01       Impact factor: 5.790

3.  Coadministration of posaconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients.

Authors:  R Greco; M C Barbanti; M T Lupo Stranghellini; F Giglio; M Morelli; C Messina; A Forcina; C Oltolini; S Piemontese; P Scarpellini; S Marktel; A Assanelli; M Carrabba; L Vago; C Corti; M Bernardi; J Peccatori; F Ciceri
Journal:  Bone Marrow Transplant       Date:  2016-04-25       Impact factor: 5.483

4.  Critical review of current clinical practice guidelines for antifungal therapy in paediatric haematology and oncology.

Authors:  Jessica E Morgan; Hadeel Hassan; Julia V Cockle; Christopher Lethaby; Beki James; Robert S Phillips
Journal:  Support Care Cancer       Date:  2016-09-11       Impact factor: 3.603

Review 5.  Recommendations for Risk Categorization and Prophylaxis of Invasive Fungal Diseases in Hematological Malignancies: A Critical Review of Evidence and Expert Opinion (TEO-4).

Authors:  Can Boğa; Zahit Bolaman; Seçkin Çağırgan; İhsan Karadoğan; Mehmet Ali Özcan; Fahir Özkalemkaş; Rabin Saba; Mehmet Sönmez; Esin Şenol; Hamdi Akan; Murat Akova
Journal:  Turk J Haematol       Date:  2015-06       Impact factor: 1.831

6.  Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study.

Authors:  R T Maziarz; R Brazauskas; M Chen; A A McLeod; R Martino; J R Wingard; M Aljurf; M Battiwalla; C C Dvorak; B Geroge; E C Guinan; G A Hale; H M Lazarus; J-W Lee; J L Liesveld; M Ramanathan; V Reddy; B N Savani; F O Smith; L Strasfeld; R A Taplitz; C Ustun; M J Boeckh; J Gea-Banacloche; C A Lindemans; J J Auletta; M L Riches
Journal:  Bone Marrow Transplant       Date:  2016-12-19       Impact factor: 5.483

7.  Saprochaete clavata Invasive Infections - A New Threat to Hematological-Oncological Patients.

Authors:  Vladimir Buchta; Radka Bolehovská; Eva Hovorková; Oliver A Cornely; Danila Seidel; Pavel Žák
Journal:  Front Microbiol       Date:  2019-10-29       Impact factor: 5.640

8.  Caspofungin for primary antifungal prophylaxis after T-cell-replete haploidentical stem cell transplantation with post-transplant cyclophosphamide.

Authors:  Jacopo Mariotti; Chiara De Philippis; Stefania Bramanti; Barbara Sarina; Federica Tordato; Daria Pocaterra; Erminia Casari; Carmelo Carlo-Stella; Armando Santoro; Luca Castagna
Journal:  Eur J Haematol       Date:  2019-02-13       Impact factor: 2.997

9.  Comparison of Three Distinct Prophylactic Agents Against Invasive Fungal Infections in Patients Undergoing Haplo-identical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide.

Authors:  Jean El-Cheikh; Roberto Crocchiolo; Andrea Vai; Sabine Furst; Stefania Bramanti; Barbara Sarina; Angela Granata; Catherine Faucher; Bilal Mohty; Samia Harbi; Reda Bouabdallah; Norbert Vey; Armando Santoro; Christian Chabannon; Luca Castagna; Didier Blaise
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-08-20       Impact factor: 2.576

10.  Antifungal prophylaxis of patients undergoing allogenetic hematopoietic stem cell transplantation in China: a multicenter prospective observational study.

Authors:  Lei Gao; Yuqian Sun; Fanyi Meng; Mingzhe Han; He Huang; Depei Wu; Li Yu; Hanyun Ren; Xiaojun Huang; Xi Zhang
Journal:  J Hematol Oncol       Date:  2016-09-23       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.